Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cfMSC Therapy for Type II Diabetes Mellitus
NCT07495956Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2027
- Primary completion
- Jun 2029
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of clonal fetal mesenchymal stem cells in type 2 diabetes mellitus (T2DM), sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Jun 2027; status: not yet recruiting.
02
Drugs
clonal fetal mesenchymal stem cells
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07495956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495956.